

AutoNetCan Webserver User Manual

**Automated Biomolecular Network Construction for Translational Cancer Systems
Biology**

(Version 1.0)

Table of Contents

Getting Started: Select a Cancer Type.....	3
1. Node Set Acquisition	4
1.1 Differentially Expressed Genes (DEGs).....	4
1.2 Frequently Mutated Genes.....	6
1.3 Therapeutically Targetable Nodes.....	6
1.3.1. FDA-Approved Therapies	7
1.3.2. Clinical Trial-Based Therapies	7
1.3.3. Experimental Therapies (Cell Line-Based).....	9
1.3.4. DNA Repair Pathway Genes	9
1.4 Cancer Signature Genes	11
2. Node Set Enrichment.....	13
3. Connectivity Mapping	15
4. Omics Data-based Logical Rules Modeling	16
5. Final Review and Submission	18

Getting Started: Select a Cancer Type

AutoNetCan is designed to facilitate the automated construction of cancer-type-specific biomolecular networks. The process begins with the selection of a target cancer type using a drop-down menu in the platform interface (**Figure 1**).




Figure 1: Cancer Type Selection Interface

The user selects from a list of 28 predefined cancer types sourced from the Genomic Data Commons (GDC). Once the cancer type is selected, AutoNetCan guides the user through a structured four-step workflow to build a network:

1. **Node Set Acquisition** – Assemble biologically relevant genes from curated datasets.
2. **Node Set Enrichment** – Expand the node list by identifying enriched pathways and gene sets.
3. **Connectivity Mapping** – Define molecular interactions by integrating known regulatory relationships.
4. **Logical Rules Modeling** – Infer logical rules governing gene regulation using transcriptomic data.

Each step is outlined in detail in the sections below, with clear guidance on user input, available options, and output files generated at every stage.

1. Node Set Acquisition

This is the first stage of network construction, where AutoNetCan gathers an initial node set (genes/nodes) relevant to the selected cancer type. Nodes are acquired from multiple high-quality sources to ensure a comprehensive starting network. These sources include:

- **Differentially Expressed Genes (DEGs):** Genes significantly up- or down-regulated in the cancer tissue compared to normal tissue.
- **Frequently Mutated Nodes:** Genes with high mutation frequency in the cancer cohort.
- **Therapeutically Targetable Nodes:** Genes that are targets of known cancer therapies (approved drugs, clinical trial drugs, or experimental compounds), including DNA repair genes.
- **Oncogenes, Tumor Suppressors, and Driver Genes:** Known cancer-associated genes curated from literature.
- **Cancer-Specific Gene Panels:** Genes from diagnostic or prognostic panels specific to certain cancers.

Each category above can be selected to include the corresponding nodes in the network. The web interface will guide you through each in sequence.

Tip: At each step of node acquisition, you may enable the “*Download detailed file(s) for this step*” option to obtain a comprehensive output file for that step. By default, AutoNetCan will always produce a summary list of nodes for each step, but enabling this option provides full details for advanced analysis.

1.1 Differentially Expressed Genes (DEGs)

The cancer type selected determines which data (expression, mutations, etc.) will be used from the Genomic Data Commons. After choosing the cancer type, users have the option to specify parameters for differential gene expression analysis (**Figure 2**).

2 Differential Gene Expression Parameters

Set the thresholds for differential gene expression analysis. These parameters help identify significantly up/down-regulated genes.

Minimum Log₂ Fold Change

Maximum Log₂ Fold Change

p-Value

Download detailed file(s) for this step

Figure 2: Differential Gene Expression Parameters

Users can provide thresholds to identify significant DEGs by setting the minimum and maximum log₂ fold-change and a p-value cutoff for significance. Once parameters are entered (or defaults are used), click “Next” to proceed.

Note: Some cancer types (e.g., bone, eye, lymph nodes, nervous system, ovary, pleura, testis) do not have normal tissue samples in Genomic Data Commons (GDC). In those cases, the DEGs step is skipped because differential expression cannot be computed for those cancers.

Input Parameters

- **Minimum Log₂ Fold Change:** Lower bound for gene expression fold-change (default -2).
- **Maximum Log₂ Fold Change:** Upper bound for fold-change (default +2).
- **p-Value Threshold:** Significance cutoff for differential expression (default 0.05).

Output

- **Detailed DEGs File** – Comprehensive list of all genes tested, each with its log₂ fold-change, p-value, adjusted p-value, etc.
- **Summary DEGs File** – A summary list of significantly up-regulated and down-regulated genes (nodes) meeting the thresholds. This provides the set of DEGs that will be included in the network.


DESeq2 Analysis

For the selected cancer type, differential gene expression analysis is performed using DESeq2 [55], an established method for analyzing RNA-Seq data. The platform triggers the DESeq2 analysis once the DEGs parameters have been defined and the necessary files (counts and metadata) are available. DESeq2 evaluates gene expression by comparing tumor and normal tissue samples, identifying genes that are differentially expressed.

1.2 Frequently Mutated Genes

AutoNetCan allows users to optionally include genes that are frequently mutated in the selected cancer type (Figure 3). Upon selecting this option, AutoNetCan automatically fetches relevant mutational frequency data from the Genomic Data Commons (GDC) API.

To include these genes, simply tick the checkbox labeled “*Acquire nodes based on their mutational frequency*” No additional parameters are required — AutoNetCan will fetch the relevant genes using default criteria via the GDC API. Once selected, click “*Next*” to continue.



The screenshot shows a step titled "3 Mutational Frequency". Below the title is a descriptive text: "Enable this option to include nodes based on their mutation frequency in cancer samples." There are two checkboxes: the first is "Acquire nodes based on their mutational frequency" and the second is "Download detailed file(s) for this step". Both checkboxes are currently unchecked.

Figure 3: Mutational Frequency Option

Input Parameters

- **Include Mutated Genes:** Checkbox to include genes with high mutation frequency in the selected cancer cohort (optional).

Output

- **Detailed Mutational Frequency File** – List of genes with their mutation statistics (e.g., number of tumor samples with mutations, copy number variations, etc.) in the cohort, along with relevant annotations.
- **Summary Mutational Frequency File** – A unique list of high-frequency mutated genes identified for the cancer. These genes will be added as nodes in the network.

1.3 Therapeutically Targetable Nodes

In this step, you can expand the node set to include genes that are targeted by various cancer therapies. AutoNetCan allows you to incorporate: **(a)** targets of FDA-approved

drugs, **(b)** targets of drugs in clinical trials, **(c)** targets of experimental compounds (e.g., from cell-line screens), and **(d)** genes from selected DNA repair pathways. You can choose any combination of these to enrich the network with clinically relevant nodes.

1.3.1. FDA-Approved Therapies

These are nodes targeted by drugs already approved for cancer treatment (chemotherapies, targeted therapies, immunotherapies, hormonal therapies, etc.). AutoNetCan curates drug–target relationships from public cancer therapy database.

4 FDA Approved Therapies

Select nodes that are targeted by FDA-approved therapeutic approaches. This helps identify clinically validated targets.

Chemotherapy

Targeted Therapy

Immunotherapy

Hormonal Therapy

Unclassified

Download detailed file(s) for this step

Figure 4: FDA-Approved Therapy Targets

Select one or more categories of FDA-approved treatments whose target genes you want to include. For example, you may check *Chemotherapy*, *Targeted Therapy*, *Immunotherapy*, *Hormonal Therapy*, and/or *Unclassified* to include drug targets from those categories (Figure 4). After choosing the therapy categories, click “Next” to proceed.

Input Parameters

- **Therapy Category Selection:** Check one or more drug categories to include their target genes (e.g., chemotherapy, immunotherapy).

Output

- **Detailed Drug Targets File** – Includes drug names, approval status, therapy category, and corresponding target genes.
- **Summary Drug Targets File** – Unique list of therapy-associated nodes added to the network.

1.3.2. Clinical Trial-Based Therapies

Nodes targeted by drugs that are currently in clinical trials, retrieved from ClinicalTrials.gov data, can also be added.

5 Clinical Trials

Include nodes that are currently being investigated in clinical trials at different phases of development.

Select nodes targeted by clinical trials based therapies

Early Phase I

Phase I

Phase II

Phase III

Phase IV

Download detailed file(s) for this step

Figure 5: Clinical Trial Therapy Selection

If desired, include targets of trial-phase drugs by selecting the trial phases. For instance, check *Phase I*, *Phase II*, *Phase III*, etc., to include gene targets of therapies in those trial stages (**Figure 5**). You can select any or all phases. After selecting, click “*Next*” to continue.

Input Parameters

- **Trial Phases:** Select one or more phases (Early Phase I, Phase I–IV) to include associated drug targets.

Output

- **Detailed Clinical Trial Targets File** – A list of drugs, trial phases, and their associated gene targets.
- **Summary Clinical Trial Targets File** – Unique list of genes associated with selected trial-phase therapies.

1.3.3. Experimental Therapies (Cell Line-Based)

To include experimental drug target nodes, provide a Z-score threshold (**Figure 6**). Z-score reflects sensitivity — the lower (more negative) the score, the more sensitive the cell line is to the drug. Adjust this cutoff as needed and click “Next”.



6 Experimental Therapies

Set the Z-Score threshold for including experimental therapeutic targets. Higher Z-scores indicate stronger experimental evidence.

Z-Score

0

Download detailed file(s) for this step

Figure 6: Experimental Therapy z-score filter

Input Parameters

- **Z-Score Threshold:** Provide a z-score value (default: 0). Negative values indicate higher sensitivity.

Output

- **Detailed Experimental Targets File** – Includes drug name, z-score, dataset type (GDSC1/GDSC2), and target genes.
- **Summary Experimental Targets File** – Unique list of high-sensitivity experimental drug targets.

1.3.4. DNA Repair Pathway Genes

You may also enrich the network with genes from DNA damage repair pathways, as these are often crucial in cancer. AutoNetCan includes predefined sets of DNA repair genes from the REPAIRtoire database (covering pathways like DNA Damage Signaling, Base Excision Repair, Mismatch Repair, etc.) (**Figure 7**).

7 Repair Pathways

Select DNA repair pathways to include in your network. These pathways are crucial for understanding cancer response and resistance mechanisms.

- DNA Damage Signaling
 - Direct Reversal Signaling
 - Direct Reversal Repair
 - Base Excision Repair
 - Nucleotide Excision Repair
 - Mismatch Repair (MMR)
 - Homologous Recombination Repair
 - Non-Homologous End Joining
 - Translesion Synthesis
-
- Download detailed file(s) for this step

Figure 7: DNA Repair Pathway Selection

Check any option for DNA repair pathway by clicking the checkbox to add all genes in that pathway as nodes. For example, choosing Mismatch Repair (MMR) will include known MMR genes in the network. After selection, click “Next”.

Input Parameters

- **Repair Pathway:** Tick the checkbox to include genes from DNA repair pathways. One or more predefined pathways can be selected.

Output

- **Repair Pathway Summary File** – Unique list of genes from the selected repair pathway.

1.4 Cancer Signature Genes

In this step, users can enrich the network by adding genes that are recognized as being significantly associated with cancer. AutoNetCan allows for the inclusion of genes from four key categories: *Tumor Suppressor Genes* (TSG), *Oncogenes*, *Driver Genes*, and genes from *Cancer-Specific Diagnostic Panels* (**Figure 8**). These genes play crucial roles in cancer development and progression, making them valuable additions to the biomolecular network.

Users can select one or more gene categories, depending on their research needs, and proceed to include them in the network construction. After making selections, users can click "Next" to proceed.

These categories can be selected individually or in combination. Once selected, click "Next" to proceed.

8 Cancer Signature Genes

Include well-known cancer-related genes such as tumor suppressors, oncogenes, and driver genes in your network.

Tumor Suppressor Genes

Oncogenes

Driver Genes

Nodes Targeted by cancer-sepcific panels

Download detailed file(s) for this step

Figure 8: Cancer Signature Genes

Input Parameters

- **Cancer Signature Gene Types:** Select one or more of the following gene types to include:
 - Tumor Suppressor Genes
 - Oncogenes
 - Driver Genes
 - Cancer Panel Nodes

Output

- **Cancer Gene Detailed File** – Detailed information for each included cancer-related gene, including its gene ID, name, its classification (oncogene, TSG, or

driver), and reference information from CancerMine (e.g. the cancer context in which it's reported).

- **Cancer Panel Detailed File** (if the “Cancer Panel Nodes” checkbox is marked) – A list of all genes from cancer-specific panel(s) relevant to the chosen cancer, with details such as the panel name, provider (company or institution), the cancer type the panel is designed for, and the date of the panel data.
- **Cancer Gene Summary File** – A unique list of all oncogenes/TSGs/drivers added to the network, with an indication of their source category.

2. Node Set Enrichment

In this step, AutoNetCan allows you to expand your existing node list by identifying additional genes that are biologically enriched in known pathways. Using Over-Representation Analysis (ORA), AutoNetCan compares your current gene list against established pathway libraries and detects significant overlap. Pathways with a significant overlap will have their genes added to your node list, thus expanding the network and potentially revealing new biological insights.

The screenshot shows a web interface for configuring node enrichment. It is titled '9 Node Enrichment' and includes a subtitle: 'Configure node enrichment parameters for pathway and functional analysis.' The interface contains several input fields and a checkbox:

- Enrichment Library:** A dropdown menu with the text 'Select Library' and a downward arrow. Below it is the text: 'The database to use for node enrichment analysis'.
- Node Sets to Enrich:** A dropdown menu with the text 'Select node sets' and a downward arrow. Below it is the text: 'Select the node sets you want to enrich'.
- Minimum Gene Set Size:** A text input field containing the number '5'. Below it is the text: 'The minimum number of genes required in a set'.
- Maximum Gene Set Size:** A text input field containing the number '500'. Below it is the text: 'The maximum number of genes allowed in a set'.
- Download Node Enrichment Files:** A checkbox that is currently unchecked. To its right is the text: 'Download the node enrichment analysis files after processing'.

Figure 9: Node Set Enrichment

To run enrichment, select one of the available gene set libraries — *MSigDB* (Molecular Signatures Database) or *Enrichr*. After selecting the library, choose the specific library files you want to include in the analysis. Set the minimum and maximum gene set size to filter out very small or very large sets (default: 5–500 genes) (Figure 9). Click “Next” to begin. AutoNetCan will compare your current node list against the selected gene sets and identify those with statistically significant overlap. Once the enriched gene sets are identified, AutoNetCan will add unique genes from the enriched sets to your node list. This expansion enhances the network, potentially identifying new biomarkers or relevant genes associated with the cancer type under study.

Input Parameters

- **Enrichment Library:** Select the source of gene sets for ORA. Options: *MSigDB* or *Enrichr*.

- **Enrichment Library Files:** Select the files from *MSigDB* (39 library files) or *Enrichr* (more than 150 files) for enrichment.
- **Minimum Gene Set Size:** Smallest gene set size to consider (default 5; gene sets with fewer genes than this will be ignored).
- **Maximum Gene Set Size:** Largest gene set size to consider (default 500; gene sets larger than this will be ignored).
- **P-adjusted threshold:** Significance cutoff for enrichment analysis (default 0.05).
-


Output

- **Enrichment Detailed File** – Detailed results for each enriched gene set/pathway: including the name of the gene set, the library/source, number of genes from your list that overlap with it, the total genes in that set, *p*-value, adjusted *p*-value, and other statistics.
- **Pathway Information File** – A summary of each significant enriched pathway/gene set (with its name and source library) and the list of node genes associated with that pathway that have been added to the network.
- **Summary File** – A compiled list of all unique new nodes added in this enrichment step, along with their source annotation.

Tip: Selecting *MSigDB* or *Enrichr* provides broad coverage of pathways and gene sets, which can be valuable for discovery. However, if your initial node list is large, consider narrowing the library selection or adjusting the gene set size filters. This helps maintain a more focused and interpretable network.

3. Connectivity Mapping

In this step, you can define the connections (edges) between the nodes in your network. AutoNetCan identifies known regulatory interactions, such as activation or inhibition, between the genes (**Figure 10**).



10 Edge Connectivity

Enable edge connections between nodes to establish relationships in your network.

Connect Edges

Download detailed file(s) for this step

Figure 10: Edge Connectivity Option

To include known interactions, make sure the *Connect Edges* option is checked. This is enabled by default. Click “*Next*” to begin the connectivity mapping. AutoNetCan will then create edges between nodes based on regulatory relationships sourced from databases such as TRRUST, INDRA, SIGNOR, and OmniPath.

Input Parameters

- **Connect Edges:** Checkbox to enable automatic retrieval of known interactions between nodes (leave this unchecked only if you prefer to construct a network without any predefined edges).


Output

- **Mapped Edges File** – A list of all interactions added to the network. Each entry includes the source node, target node, interaction type (activation or inhibition), a brief description (if available), and a reference/source for that interaction (e.g., which database or publication supports it).
- **Mapping Statistics** – A simplified count of edges found from the database for the given set of mapped nodes.
- **Summary File** – A summary of network connectivity statistics, e.g., how many incoming and outgoing edges each node has (degree of each node). This can help identify hubs or key regulatory nodes in the network.

4. Omics Data-based Logical Rules Modeling

In this step, you can define logical rules that describe how each node in the network is regulated. AutoNetCan offers two modeling options (Figure 11):

- **Expectation-Maximization (EM)** – Recommended for nodes with a small number of regulators.
- **Boolean Rules** – Uses a truth table–based method and can be applied regardless of input size.



The screenshot shows a web interface titled "11 Boolean Modelling" with the subtitle "Configure boolean modelling options for network analysis." It features a dropdown menu for "Select a GDC specific project" with the placeholder text "Select a project". Below this is a note: "Select a GDC specific project for selected cancer type for boolean modelling." Under the heading "Select Boolean Modelling Methods", it states "You can select multiple modelling methods" and lists two options: "Sample Data to Truth Table" (unchecked) and "Expectation Maximization" (unchecked). A note next to "Expectation Maximization" reads: "Only works when there are fewer than 20 source nodes per target node".

Figure 11: Boolean Modeling Option

Select the desired modeling method. Then, choose the cancer cohort (project) whose RNA-Seq expression data should be used for rule inference. Click “Next” to proceed.

Note: Only one project can be selected for the logical modeling step for the chosen cancer type. Once the project is selected, proceed to the next screen.

Tip: The EM method may take longer when nodes have many regulators. AutoNetCan limits EM-based rule inference to nodes with approximately 15 or fewer regulators.

Once the modeling is complete, you will receive an email with a link to download your output files.

Input Parameters

- **Logical Modeling Method:** Select from the following approaches for rule inference:
 - *Expectation-Maximization (Probabilistic)* – learns logic rules by fitting a probabilistic model to expression data.
 - *Boolean (Deterministic)* – infers logical rules by analyzing binary expression patterns (truth-table approach).
- **Expression Data (Project):** Select a cancer project (e.g., TCGA-BRCA) to use for RNA-Seq input. Only one can be selected.


Output

- **Network Rules File (Cytoscape format):** A complete network file including nodes, edges, and inferred logical rules. Compatible with Cytoscape for visualization and editing.
- **Network Rules File (TISON format):** A file containing the same network and rules, formatted for simulation and perturbation analysis in the TISON platform.
- **Network Object (JSON format):** An additional JSON file is provided for advanced processing or integration with other tools, if needed.

Note: After downloading your output files, you can visualize and explore the network using Cytoscape or simulate its behavior using TISON. Steps to view the network in Cytoscape and TISON are mentioned below.

5. Final Review and Submission


As one of the final steps in the workflow, you will be asked to provide your email address within the form (Figure 12). AutoNetCan will use this to notify you when your network construction is complete and send a link to download the results.



The screenshot shows a form titled "12 Contact Information". Below the title is a horizontal line, followed by the instruction: "Please provide your email address to receive updates and results for your network generation process." Below this is the label "Email Address" and a text input field containing the placeholder text "Enter your email address". At the bottom of the form, there is a note: "We'll send you updates about your network generation progress and notify you when it's ready."

Figure 12: Contact Information

After providing your email, click “Review” to continue. You will then see a preview page that summarizes all your selections from each step — including cancer type, thresholds, selected categories, and enrichment settings (Figure 13).



The screenshot shows a page titled "13 Preview Your Selections". Below the title is a horizontal line, followed by the instruction: "Review all your selections before creating the network. Make sure all parameters are set correctly." Below this is a list of four sections, each with a numbered header and a list of parameters:

- 1 Cancer Type**
 - Selected Cancer: Not selected
- 2 Gene Expression Parameters**
 - Minimum Log2 Fold Change: -2
 - Maximum Log2 Fold Change: 2
 - p-Value: 0.05
 - Download Detailed Files: No
- 3 Mutational Frequency**
 - Status: Disabled
 - Download Detailed Files: No
- 4 FDA Approved Therapies**

Figure 13: Preview Your Selections

Carefully review all parameters, if something needs to be changed, go back and edit it. Once everything looks correct, click “*Submit*” to start the network construction job. AutoNetCan will begin processing and notify you by email once your results are ready.

6. Network Visualization

The constructed network can be visualized using several platforms, including AutoNetCan, Cytoscape, and TISON.

6.1 Network Visualization in AutoNetCan

After the network construction is complete, users receive an email notification. This email includes a link to download the results via the "*Download Results*" option, as well as a "*Visualize Network*" button that redirects to the AutoNetCan page (**Figure 14**).




Figure 14: Email notification containing links to download result files and visualize the network.

On the AutoNetCan platform, the network can be viewed using various layout options such as circular, grid, or force-directed layouts (**Figure 15**). Users can interact with the network by searching for specific nodes through the search bar or by clicking directly on nodes to explore their incoming and outgoing interactions (**Figure 16**).




Figure 15: Network visualization interface in AutoNetCan.

MAPK1

Total Nodes 932 Total Edges 4178

Selected Node Details

Name: MAPK1
 UniProt: MAPK1
 Ensembl: ENSG00000100030
 Alternative Names: ERK2, PRKM1, PRKM2

Connected Edges 132

Source	Target	Interaction
ADRB2 Source: INDRA	MAPK1	Activates
ITGAV Source: INDRA	MAPK1	Activates
KIT Source: INDRA	MAPK1	Activates
KRAS Source: INDRA	MAPK1	Activates
LEP Source: INDRA	MAPK1	Activates
LIFR Source: INDRA	MAPK1	Activates
DRADC		

Figure 16: Visualization of the node search feature in AutoNetCan, highlighting MAPK1 with 132 total incoming and outgoing interactions.

6.2 Network Visualization in Cytoscape

AutoNetCan generates a .csv file with a structured format that can be seamlessly imported into Cytoscape for network visualization. Follow these steps:

1. Launch Cytoscape (desktop version 3.10.3). Go to File → Import → Network from File (**Figure 17**).
2. In the Network file to load window, locate and select the .csv file generated by AutoNetCan (**Figure 18**).
3. The Import Network from Table window will open. Column headers will be automatically mapped to:
 - Source Node
 - Target Node
 - Interaction Type
 - Edge Attribute
 - Edge Color

Click OK to import the network (**Figure 19**).

4. Once the network is loaded (**Figure 20**), go to the Style tab, then select the Edge sub-tab (**Figure 21**).
5. Under Stroke Color, click the dropdown arrow, set the column to Edge Color, and choose Passthrough Mapping as the mapping type (**Figure 22**).
6. For Target Arrow Shape, click the dropdown, select Edge Color as the column, and again choose Passthrough Mapping (**Figure 23**).
7. The network will now appear on the canvas with directed and color-coded edges representing the type and attributes of interactions (**Figure 24**).




Figure 17: Import network in Cytoscape desktop window through “Network from File” option.




Figure 18: Sample Network upload window




Figure 19: Import Network from Table window and assignment of network variables.




Figure 20: Visualization of nodes and undirected edges in Cytoscape.




Figure 21: Network tab and Edge sub-tab on the left panel of window.




Figure 22: Assignment of edge color




Figure 23: Assignment of target arrow shape




Figure 24: Network visualization with directed and colored edges in Cytoscape.

6.3 Network Visualization in TISON

AutoNetCan generates .txt file which can be uploaded in TISON by following these simple steps:

1. Visit <https://tison.lums.edu.pk> and click on “Project Explorer” (**Figure 25**).
2. Click “Create a New Project” and assign a name (e.g., CaseStudy) (**Figure 26 - Figure 28**).
3. Open the newly created project and navigate to the “Networks” editor (**Figure 29**).
4. Click the “Create Network” button (the ‘+’ icon) (**Figure 30**).
5. In the pop-up window, select “Write Rules” (**Figure 31**).
6. Paste the .txt file generated by AutoNetCan’s logical modeling step and click “Create Network” (**Figure 32**).
7. Network with nodes and edge count visible on the canvas in TISON (**Figure 33**).

The screenshot shows the TISON homepage. At the top left is the TISON logo. To the right is a navigation menu with links for Home, Features, Editors, About, Team, and Contact. Below the logo is the text 'Theatre for In silico Systems Oncology' and 'A Next-Generation Multi-scale Modeling and Simulation Platform for Cancer Systems Oncology'. Two white boxes display statistics: 'Networks 9662' and 'Therapeutics 4398'. Below these are two buttons: 'Project Explorer' (highlighted with a red border) and 'Documentation'. A 'FEATURES' section is centered below, listing six categories: Biomolecular Network Modelling, Network Analysis & Therapeutics, Targeted Therapies, Combinatorial Drug Assessment, Target Identification, and Precision Medicine. The footer contains the copyright notice '© 2024 TISON is freely available for every user, including commercial users.' and links for Home, Privacy Policy, and Terms of Use.

Figure 25: TISON homepage displaying the Project Explorer tab used to create projects.

PROJECT EXPLORER

Sample Project



World Size
100 x 100 x 100

Created: Mar 14 2025 7:22PM
Updated: Mar 14 2025 7:22PM

Figure 26: Create a New Project tab in Project Explorer

Create a New Project

Project Name:

World Size:

Upload Image
 No file chosen 

Description:

Figure 27: Details required by TISON for creating a new project




Figure 28: Case Study Project




Figure 29: Navigate to Networks Editor




Figure 30: Click the “Create Network” button




Figure 31: Select “Write rules” option to create network




Figure 32: Rules editor window




Figure 33: AutoNetCan generated network visualization in TISON